Never get surprised at the pharmacy counter by an expired prior auth.
KeepMyAuth is a reminder and paperwork-help service for any drug that requires a prior authorization — with GLP-1s such as Wegovy, Zepbound, Ozempic, and Mounjaro as the first focus. We watch the dates, warn you 30 or more days before a prior auth expires or before January 1 plan changes, and give you a renewal request that’s ready to send to your doctor. That means less time on the phone with pharmacies and doctors, and less stress at the pickup window. We do not approve coverage, and we do not give medical advice.
Developed by a retail pharmacist with 31 years of experience.
Less time on the phone with pharmacies and doctors
Less stress at the pickup window
For any drug that requires a prior auth
Founding member preorders, refundable if we don’t launch
Why this happens
Approvals can run out before anyone tells you.
A prior authorization is not open-ended. On GLP-1s — the first example this service is built around — some approvals last only a few months, and January 1 is when many plans change weight-loss coverage or the preferred product. The same surprise can happen with any medicine that needs a PA. The figures below are examples from published plan documents and surveys, not a promise about your plan.
5–6 months
UnitedHealthcare’s published 2026 weight-loss policy lists an initial prior auth of 5 months for Wegovy and 6 months for Zepbound. Saxenda is listed at 4 months. If the plan’s reauthorization criteria are met, a later approval may be 12 months.
Cigna’s Zepbound weight-loss policy uses an 8-month initial authorization. Continuation may be approved for a year if the plan’s criteria are met, including a documented percent of weight loss from the plan’s defined baseline.
A SHRM report on a Business Group on Health survey of large employers says 14% have already dropped or plan to drop GLP-1 coverage for weight management by 2027. That is a survey of large employers, not a share of all patients.
Optum Rx’s 2027 Premium Standard Formulary lists Saxenda and the Zepbound KwikPen and vials as excluded. Even a product that still appears on the list may depend on whether an employer bought the weight-loss benefit.
These examples can change. Your approval letter and your live plan policy are what matter for your medicine. KeepMyAuth does not guarantee that coverage will continue.
Why a lapse matters
A gap in a GLP-1 can mean starting over.
If a prior auth lapses and you go without the medicine for a stretch, restarting is often not as simple as picking up the old dose. That is one reason to begin the renewal early. This is not medical advice, and it is not a prediction about your own care. Talk with your prescriber before you miss doses or change a dose.
You may have to restart at a lower dose — and stomach side effects can return.
After a gap, many people cannot simply resume the dose they were on. The Wegovy injection prescribing information says that if two or more consecutive weekly doses are missed, the prescriber may restart treatment and follow the usual dose-escalation schedule, “which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment.” The Ozempic, Zepbound, and Mounjaro labels also tell clinicians to follow a gradual escalation schedule to reduce the risk of gastrointestinal side effects, and they note that nausea, vomiting, and diarrhea are most often reported during dose escalation.
Those schedules typically increase the dose only after at least four weeks at each step. On the labeled Wegovy injection schedule, a maintenance dose does not begin until week 17. Re-titration can mean weeks before you are back at the dose that was working. Do not change your dose on your own — ask your prescriber what to do after missed doses or a coverage gap.
In the STEP 1 extension, adults without diabetes who stopped weekly semaglutide 2.4 mg after 68 weeks (mean loss 17.3%) regained 11.6 percentage points by week 120 — about two-thirds of what they had lost, for a net loss of 5.6% from the start. In STEP 4, people who switched to placebo after a 20-week run-in gained 6.9% from that point over the next 48 weeks, while those who continued lost another 7.9%. In SURMOUNT-4, after a 20.9% mean loss on tirzepatide, people switched to placebo gained 14.0% over the next 52 weeks; those who continued lost another 5.5%. These are group averages from trials, not a promise about you.
The STEP 1 extension reported that cardiometabolic improvements seen during 68 weeks of semaglutide reverted toward baseline one year after the drug was stopped, for most variables that were tracked. In STEP 4, people who continued semaglutide also did better than those who switched to placebo on waist circumference and systolic blood pressure. Those withdrawal studies enrolled people without diabetes. If you take a GLP-1 for type 2 diabetes, a gap can also affect blood-sugar control — another reason to talk with your prescriber early.
A coverage lapse is not the same as a planned trial withdrawal, but both can mean time off the medicine. KeepMyAuth cannot prevent a lapse by itself and does not guarantee that a renewal will be approved. We aim to give you time to start the paperwork before a gap happens.
Medicare and GLP-1s
The Medicare GLP-1 Bridge, explained
If you have Medicare Part D and take a GLP-1 for weight management, a temporary federal program — the Medicare GLP-1 Bridge — can be easy to mix up with regular Part D coverage. KeepMyAuth can help you track the dates and the paperwork. We do not decide whether you qualify, and this is not coverage advice. Confirm the current rules with your prescriber and with Medicare.
Temporary, and separate from Part D
The Bridge is a short-term CMS demonstration. It started July 1, 2026, and is currently set to end December 31, 2027. It runs outside your regular Part D benefit: your plan does not have to opt in, and a central CMS processor — not your usual plan — handles the prior authorization and the pharmacy claim.
If you qualify, you pay a $50 copay for a one-month supply. Because this is not regular Part D coverage, that $50 does not count toward your Part D deductible or yearly out-of-pocket limit, Extra Help does not lower it, and you cannot spread it out with the Medicare Prescription Payment Plan. A prior authorization is required. Medicare.gov says that authorization stays valid, including for refills and dose changes, through December 31, 2027, unless you change GLP-1 medicines.
The Bridge covers Wegovy (injection or tablet), Foundayo, and Zepbound KwikPen only — not Zepbound single-dose vials or pens. Ozempic and Mounjaro are not Bridge products. You must have Part D and meet clinical criteria (including BMI thresholds at the time you start the medicine, plus a lifestyle-modification attestation). If you already get a GLP-1 through Part D, or you take one for type 2 diabetes, moderate-to-severe sleep apnea, or MASH / fatty liver disease, Medicare says you stay with your Part D plan, not the Bridge.
CMS extended the Bridge through 2027 after delaying the related Part D “BALANCE” model for 2027. Official memos talk about a possible later move into Part D, but they do not promise a start date after December 31, 2027. That end date is one more calendar item worth watching so you and your doctor are not surprised if the rules change.
For eligibility questions, start at Medicare.gov/glp1bridge or call 1-800-MEDICARE (1-800-633-4227). KeepMyAuth does not determine Medicare eligibility and cannot promise that coverage will continue.
The service
How it works
Three steps, for any drug that requires a prior authorization. You stay in charge of your care. We handle the calendar and prepare the paperwork, so you spend less time on the phone with pharmacies and doctors — and less time stressing at the counter.
1
Share what’s already approved
When the service opens, you tell us the medicine, your plan, the approval and expiration dates, and your prescriber’s office. The waitlist does not ask for any of that.
2
We watch the calendar
You get a warning 30 or more days before an approval ends, with follow-up reminders as the date gets closer, plus a January 1 check for plan and formulary changes.
3
Your doctor gets a renewal request
We prepare a ready-to-send request you can give your prescriber. For $29, a pharmacist can follow up with the office and the plan — with your written permission — until there’s a status to report. Less phone tag for you.
Pricing
Simple, honest pricing
Founding member preorders are refundable if we don’t launch. This is a reminder and paperwork-help service, not insurance and not a medical benefit. It works for any drug that needs a prior auth. Preorders aren’t open yet — join the waitlist and we’ll email you when they are.
Watch
We track it. You stay ahead.
$5 / month
Founding member preorder · refundable if we don’t launch
We track your prior auths — any medicine that needs one, with GLP-1s as the first focus
Warnings 30 or more days before an approval expires
A January 1 checklist for plan and formulary changes
A ready-to-send renewal request for your doctor, so you spend less time on the phone
Preorders aren’t open yet. This button takes you to the waitlist. No payment will be taken from this page.
Pharmacist-chased renewal
A pharmacist follows through.
$29 one time
Founding member preorder · refundable if we don’t launch
A ready-to-send renewal request for that authorization
A licensed pharmacist contacts your prescriber’s office, with your written permission
Follow-up with the plan or PBM, with your permission — less phone tag for you
A clear status: submitted, approved, denied, or needs more information
Not a guarantee of approval
Preorders aren’t open yet. This button takes you to the waitlist. No payment will be taken from this page.
31years as a retail pharmacist
Developed by a retail pharmacist with 31 years of experience.
Our founder started KeepMyAuth after seeing too many people find out at the pickup window that last season’s approval had run out — and then spend hours on the phone with pharmacies and doctors.
The service is for any drug that requires a prior authorization. The first focus is GLP-1s — Wegovy, Zepbound, Ozempic, Mounjaro, and related medicines such as Saxenda — because those authorizations are often short, the paperwork is exacting, and January 1, 2027 is when many plans are changing coverage. Other prior-auth medicines are welcome from the start.
KeepMyAuth is an independent consumer service. It is not affiliated with any insurer, pharmacy benefit manager, pharmacy chain, drug maker, or government agency.
Your information
Your privacy
We will never sell or share your information. We collect only what is needed to track your authorizations. We do not use ad trackers. We contact your doctor or pharmacy only with your written permission.
We will never sell your information, or share it for advertising or for other companies’ marketing.
The waitlist asks only for a first name and email. Please do not enter medical details there.
If you use the paid service, we collect only what is needed to track your authorizations and prepare a renewal request.
We contact your doctor or pharmacy only with your written permission.
We do not put advertising or ad-tracking pixels on this site. A simple, privacy-respecting visitor count may be used later so we can tell how many people open the page. That is not an ad tracker.
We do not claim to be HIPAA compliant or HIPAA certified. A payment or email vendor may see only what it needs to complete a checkout or a waitlist signup. See our draft privacy page, which is pending lawyer review.
Questions
FAQ
Does this work only for Wegovy, Zepbound, Ozempic, or Mounjaro?
No. KeepMyAuth is for any drug that requires a prior authorization. GLP-1s are the first focus because those approvals are often short and the January 1 plan-year changes are significant, but other prior-auth medicines are welcome too.
What do I actually get out of this?
A warning before a prior auth expires, a renewal request that is ready to send to your doctor, and — if you choose the pharmacist-chased renewal — follow-up with the office and the plan, with your written permission. The aim is less time on the phone with pharmacies and doctors, and less stress at the pharmacy counter. We still cannot guarantee that a plan will approve coverage.
What happens if a GLP-1 prior auth lapses and I miss doses?
After a gap, many people cannot simply restart at the previous dose. The Wegovy injection label says that if two or more consecutive doses are missed, the prescriber may restart the medicine and follow the dose-escalation schedule, which may reduce gastrointestinal side effects that can come with starting again. The Ozempic, Zepbound, and Mounjaro labels also say to escalate the dose gradually to reduce those side effects, and they note that nausea, vomiting, and diarrhea are most often reported during dose escalation. Getting back to a maintenance dose on those schedules can take weeks. This is not medical advice. Talk with your prescriber; do not change your dose on your own. Planned trial withdrawals have also been followed by weight regain and by cardiometabolic markers drifting back toward baseline — group averages, not a prediction about you.
I’m on Medicare. What is the GLP-1 Bridge program?
It is a temporary CMS demonstration, separate from regular Part D, that started July 1, 2026, and is currently set to end December 31, 2027. Eligible people with Part D can get certain weight-management GLP-1s — Wegovy (injection or tablet), Foundayo, and Zepbound KwikPen — for a $50 monthly copay after a prior authorization. That $50 does not count toward your Part D deductible or yearly out-of-pocket limit, and Extra Help does not lower it. If you already get a GLP-1 through Part D, or you take one for type 2 diabetes, moderate-to-severe sleep apnea, or MASH, you generally stay with your plan, not the Bridge. Medicare.gov says a Bridge prior authorization stays valid through December 31, 2027, unless you change medicines. What, if anything, replaces the program after that date is not settled. KeepMyAuth can help you track those dates and the paperwork for your doctor. We do not decide eligibility. Check Medicare.gov/glp1bridge or call 1-800-MEDICARE, and talk with your prescriber.
Will my prior authorization automatically expire on January 1?
Not always. If you stay on the same plan and the approval hasn’t reached its end date, it may still be valid. January 1 is risky because formularies, prior-auth rules, and pharmacy benefit managers often change on the new plan year — and some large employers are dropping or tightening weight-loss GLP-1 coverage for 2027. Some plans only accept a new request on or after January 1. We watch both the expiration date and the plan year. We cannot promise that your coverage will continue.
What does a GLP-1 renewal usually need?
It depends on the plan and on whether the drug is covered for weight loss or for diabetes. Many weight-loss policies ask for a percent of weight lost from a defined baseline (5% is common on some published UnitedHealthcare and Cigna policies; some plans use a different number), plus continued lifestyle changes and a current weight. We help you and your doctor gather what the plan asks for. We do not guarantee approval, and we do not give medical advice about your dose or your weight.
Do you guarantee the renewal will be approved?
No. Coverage decisions belong to your plan. We help you start the paperwork early and keep track of the status. A denial can still happen, and coverage can still change.
Is this insurance, a medical benefit, or medical advice?
No. KeepMyAuth is a reminder and paperwork-help service. We do not sell insurance, we do not provide a medical benefit, and we do not diagnose, prescribe, or tell you to start or stop a medicine. Talk with your own doctor and pharmacist about your care.
Are you part of my insurance company or pharmacy?
No. KeepMyAuth is an independent consumer service. We are not affiliated with any insurer, pharmacy benefit manager, pharmacy chain, drug maker, or government agency, and we don’t speak for them. Mentions of medicine or plan names are for explanation only.
Will you sell or share my information?
No. We will never sell or share your information for advertising or for other companies’ marketing. We collect only what is needed to track your authorizations. We do not use ad trackers. We contact your doctor or pharmacy only with your written permission. The waitlist asks only for a first name and email — please do not enter medical details there. We do not claim to be HIPAA compliant or HIPAA certified. A payment or email vendor may see only what it needs to complete a checkout or a waitlist signup. See our draft privacy page for more, pending lawyer review.
What is a founding member preorder?
It’s a way to reserve the Watch plan ($5 a month) or a pharmacist-chased renewal ($29 one time) before the service is fully open. If we do not launch, that preorder is refundable. Preorder buttons will go to a secure Stripe checkout when payments are turned on; no card details are entered on this website.
What if you don’t launch?
Founding member preorders are refundable if we don’t launch. Joining the waitlist costs nothing and does not enroll you in a paid plan.
Stay in the loop
Join the waitlist
Leave your first name and email and we’ll tell you when founding member preorders are open and when the service is ready. Please do not enter medical details. This preview form does not send or store your information.